Shares of Evolent Health, Inc. (NYSE:EVH) recorded 13.87% gain during trading session on November 7th, 2018. The script traded as low as $23.31 and last traded at $26.03. 2.89 million shares changed exchanged hands during trading, a drop of -317065.63% from the 30-day average session volume of 910.89K shares. The firm had previously closed at $22.86. The company has $82.26M outstanding shares, a price-to-earnings ratio of N/A, price-to-earnings-growth ratio of 4.23 and a beta of 1.50. The company has a RSI of 60.49, ATR of 1.40 and a volatility of 6.21% this week. EVH has a 52 week low price of $10.30 and a 52 week high price of $29.05.
Investors have identified the tech company Evolent Health, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 2.14B, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Evolent Health, Inc. (EVH) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For EVH, the company has in raw cash 251.64 million on their books with 39.48 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0 total, with 0 as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
EVH were able to record 0 as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 0. In cash movements, the company had a total of 0 as operating cash flow.
Potential earnings growth for Evolent Health, Inc. (EVH)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Evolent Health, Inc. recorded a total of 144.3 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.26% coming in sequential stages and their sales for the third quarter increasing by 0.03%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 69 million trying to sell their products during the last quarter, with the result yielding a gross income of 75.3 million. This allows shareholders to hold on to 82.26M with the revenue now reading -130 cents per share.
Is the stock of EVH attractive?
In related news, General Counsel Weinberg Jonathan sold 15,000 shares of the company’s stock in a transaction that recorded on September 13th, 2018. The sale was performed at an average price of 27.12, for a total value of 406,800. As the sale deal closes, the Chief Operating Officer Weinberg Jonathan now sold 70,000 shares of the company’s stock, valued at 1,925,000. Also, Chief Operating Officer Peterson Thomas III sold 30,000 shares of the company’s stock in a deal that was recorded on August 30th, 2018. The shares were sold at an average price of 25.00 per share, with a total market value of 67,868. Following this completion of acquisition, the Chief Accounting Officer now holds 6,805 shares of the company’s stock, valued at 170,125. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.50%.
8 out of 15 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Evolent Health, Inc. stock. 0 analysts has assigned a Sell rating on the EVH stock. The 12-month mean consensus price target for the company’s shares has been set at $31.36.